Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, By Region, And Segment Forecasts, 2024 - 2030

Immuno-oncology Clinical Trials Market Size, Share & Trends Analysis Report By Phase, By Design (Interventional Trials, Observational Trials, Expanded Access Trials), By Indication, By Region, And Segment Forecasts, 2024 - 2030

Immuno-oncology Clinical Trials Market Growth & Trends

The global immuno-oncology clinical trials market size is expected to reach USD 18.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 12.1% from 2024 to 2030. The rapidly growing field of Immuno-oncology has emerged as a novel therapeutic area within the oncology ecosystem, transforming the treatment of cancer.

From 2014 to 2017, the number of new immuno-oncology studies increased from 250 to almost 600, with double-digit growth rates each year as drug classes diversified. Biomarker and checkpoint inhibitor studies were primarily responsible for this rapid growth. While the immuno-oncology market is maturing in some pharmacological classes, cell therapies are exceeding all other immunotherapeutics in terms of growth. In March 2020, there were 1,483 active compounds in the pipeline for cancer cell therapy globally, indicating an increase of 472 from March 2019. The fastest-growing category was chimeric antigen receptor T (CAR-T) cell products (up 77% from 2019 to 2020).

Besides, during the Covid-19 pandemic, the number of IO drugs in development increased from 3,876 in 2019 to 4,720 in 2020, representing a 22% & 233% increase as compared to 2019 & 2017 respectively. After a moderate increase of 15% in 2019 compared to 68% between 2018 and 2017, this 22% increase indicates a return of interest in IO, despite the impact of the COVID-19 pandemic.

Immuno-oncology Clinical Trials Market Report Highlights

• Phase III dominated the market with the largest share of 53.2% in 2023. Oncology trials typically have fewer participants, are the most expensive, and involve larger sample sizes, resulting in a higher cost per participant.
• The interventional experiments accounted for more than 78.5% of the market share in 2023
• The segment of solid tumors held 55.9% of the revenue share in 2023. This is largely attributed to the rise in the prevalence of solid tumors
• North America dominated the market and accounted for the largest revenue share of 50.3% in 2020. This is due to the rising adoption of personalized medicine-focused novel treatment methods, as well as the government funding and investments

Please note The report will be delivered in 2-3 business days upon order notification.